Extended follow-up of the CYCLOFA-LUNE trial comparing two sequential induction and maintenance treatment regimens for proliferative lupus nephritis based either on cyclophosphamide or on cyclosporine A
Language English Country Great Britain, England Media print-electronic
Document type Comparative Study, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't
PubMed
24213308
DOI
10.1177/0961203313511555
PII: 0961203313511555
Knihovny.cz E-resources
- Keywords
- Lupus nephritis, cyclosporine A, systemic lupus erythematosus, treatment,
- MeSH
- Cyclophosphamide adverse effects MeSH
- Cyclosporine adverse effects MeSH
- Immunosuppressive Agents adverse effects MeSH
- Humans MeSH
- Follow-Up Studies MeSH
- Lupus Nephritis drug therapy pathology MeSH
- Cell Proliferation drug effects MeSH
- Randomized Controlled Trials as Topic methods MeSH
- Renal Insufficiency chemically induced pathology MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
- Names of Substances
- Cyclophosphamide MeSH
- Cyclosporine MeSH
- Immunosuppressive Agents MeSH
Objective To evaluate the extended follow-up of the CYCLOFA-LUNE trial, a randomized prospective trial comparing two sequential induction and maintenance treatment regimens for proliferative lupus nephritis based either on cyclophosphamide (CPH) or cyclosporine A (CyA). Patients and methods Data for kidney function and adverse events were collected by a cross-sectional survey for 38 of 40 patients initially randomized in the CYCLOFA-LUNE trial. Results The median follow-up time was 7.7 years (range 5.0-10.3). Rates of renal impairment and end-stage renal disease, adverse events (death, cardiovascular event, tumor, premature menopause) did not differ between the CPH and CyA group, nor did mean serum creatinine, 24 h proteinuria and SLICC damage score at last follow-up. Most patients in both groups were still treated with glucocorticoids, other immunosuppressant agents and blood pressure lowering drugs. Conclusion An immunosuppressive regimen based on CyA achieved similar clinical results to that based on CPH in the very long term.
References provided by Crossref.org
